The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

NAActive, not recruitingINTERVENTIONAL
Enrollment

445

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2027

Conditions
Coronary Artery DiseaseCoronary Artery StenosisCoronary DiseaseCoronary Stenosis
Interventions
DEVICE

Percutaneous Coronary Intervention

Percutaneous coronary intervention of de novo native coronary artery lesions

Trial Locations (36)

Unknown

AZ Middelheim Hospital, Antwerp

AZ Sint Jan Brugge, Bruges

Ziekenhuis Oost-Limburg, Genk

Universitaire Ziekenhuizen Leuven, Leuven

Kerkhoff Klinik GmbH, Bad Nauheim

Segeberger Kliniken GmbH, Bad Segeberg

REGIOMED Klinikum Coburg, Coburg

St. Johannes Hospital, Dortmund

Universitatsklinikum Erlangen, Erlangen

Elisabeth Krankenhaus Essen, Essen

MVZ CCB Frankfurt, Frankfurt

Universitatsklinikun Giessen, Giessen

Universitätsklinikum Jena, Jena

UKSH Kiel Klinik, Kiel

Universitätsmedizin-Mainz, Mainz

Krankenhaus der barmherzigen Bruder, Trier

Kokura Memorial Hospital, Kitakyushu

Shinkoga Hospital, Kurume

Sapporo Higashi Tokushukai Hospital, Sapporo

Takahashi Hospital, Tsuchiura

Tsuchiura Kyodo Hospital, Tsuchiura

Tenyokai Central Hospital, Kagoshima

Shonan Kamakura General Hospital, Kamakura

Kanto Rosai Hospital, Kawasaki-shi

Yokohama City Eastern Hospital, Yokohama

Kumamoto Rousai Hospital, Kumamoto

Miyazaki Medical Association Hospital, Miyazaki

Oumi Hachiman City General Medical Center, Hachiman

Cardiovascular Reaearch Institute, Tokyo

Teikyo University Hospital, Tokyo

Auckland City Hospital, Auckland

Middlemore Clinical Trials Trust, Auckland

Waikato Hospital, Auckland

Christchurch Hospital, Christchurch

Dunedin Hospital, Dunedin

North Shore Hospital, Takapuna

Sponsors
All Listed Sponsors
lead

Elixir Medical Corporation

INDUSTRY

NCT04192747 - The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries | Biotech Hunter | Biotech Hunter